Tempus AI's (TEM) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Tempus AI's stock has been reaffirmed with a "Sell (D-)" rating by Weiss Ratings, amidst mixed ratings from other analysts, including a recent downgrade by Cowen.
• The company's stock price hit $89.23 during trading, while analyst consensus suggests a hold rating with an average target price of $79.38.
• Tempus AI showed significant growth with a 89.5% increase in revenue year-over-year, reporting $314.64 million for the quarter.

Tempus AI (NASDAQ:TEM - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Several other research analysts have also recently commented on the stock. Cowen cut shares of Tempus AI from a "buy" rating to a "hold" rating in a report on Tuesday. Needham & Company LLC reissued a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research note on Friday, August 8th. Piper Sandler lifted their price objective on shares of Tempus AI from $70.00 to $105.00 and gave the company a "neutral" rating in a research note on Wednesday. Canaccord Genuity Group assumed coverage on shares of Tempus AI in a research note on Monday, October 20th. They issued a "buy" rating and a $110.00 price objective on the stock. Finally, TD Cowen cut shares of Tempus AI from a "buy" rating to a "hold" rating and set a $88.00 price objective on the stock. in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $79.38.

Tempus AI Stock Performance

Shares of TEM traded up $2.19 during mid-day trading on Friday, hitting $89.23. 4,603,921 shares of the company's stock were exchanged, compared to its average volume of 7,196,045. Tempus AI has a 52 week low of $31.36 and a 52 week high of $104.32. The stock's 50-day simple moving average is $84.20 and its 200-day simple moving average is $67.67. The firm has a market cap of $15.50 billion, a price-to-earnings ratio of -74.98 and a beta of 4.87. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company had revenue of $314.64 million for the quarter, compared to analysts' expectations of $296.84 million. During the same period last year, the firm earned ($6.86) earnings per share. The business's revenue for the quarter was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Tempus AI will post -6.15 EPS for the current year.

Insider Transactions at Tempus AI

In other news, EVP Erik Phelps sold 3,664 shares of Tempus AI stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $273,517.60. Following the transaction, the executive vice president owned 94,115 shares in the company, valued at approximately $7,025,684.75. The trade was a 3.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Ryan Fukushima sold 5,000 shares of Tempus AI stock in a transaction on Monday, October 6th. The stock was sold at an average price of $92.32, for a total transaction of $461,600.00. Following the transaction, the chief operating officer owned 130,000 shares in the company, valued at approximately $12,001,600. This trade represents a 3.70% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 933,662 shares of company stock valued at $68,070,993. Corporate insiders own 26.27% of the company's stock.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC lifted its holdings in shares of Tempus AI by 29.5% during the third quarter. Global Retirement Partners LLC now owns 733 shares of the company's stock worth $59,000 after purchasing an additional 167 shares during the period. First Horizon Advisors Inc. lifted its holdings in Tempus AI by 12.7% in the first quarter. First Horizon Advisors Inc. now owns 1,849 shares of the company's stock valued at $89,000 after buying an additional 208 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Tempus AI by 0.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company's stock valued at $2,145,000 after buying an additional 226 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Tempus AI by 6.1% in the second quarter. PNC Financial Services Group Inc. now owns 5,003 shares of the company's stock valued at $318,000 after buying an additional 287 shares during the period. Finally, Cranbrook Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at $25,000. Institutional investors and hedge funds own 24.22% of the company's stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.